Omeros (NASDAQ:OMER) CAO Sells $189,500.00 in Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the sale, the chief accounting officer owned 5,906 shares of the company’s stock, valued at $111,918.70. This represents a 62.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Performance

OMER opened at $19.25 on Friday. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65. The stock has a market capitalization of $1.39 billion, a PE ratio of 15.04 and a beta of 2.54. The business’s 50 day moving average price is $12.48 and its 200 day moving average price is $11.98.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. As a group, equities research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on OMER shares. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in Omeros during the 1st quarter worth about $357,000. XTX Topco Ltd acquired a new position in Omeros in the 2nd quarter valued at about $191,000. Invesco Ltd. increased its stake in Omeros by 34.1% during the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 29,644 shares during the period. Marshall Wace LLP increased its stake in Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after purchasing an additional 97,224 shares during the period. Finally, Sei Investments Co. acquired a new stake in shares of Omeros during the second quarter worth about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.